Precision Medicine in the Prostate Cancer Care Pathway
Precision Medicine in the Prostate Cancer Care Pathway: an Evaluation of Integrating Germline Genetic Testing Into the Management of Men at Risk of / Living With Prostate Cancer
Institute of Cancer Research, United Kingdom
3,000 participants
Feb 14, 2019
OBSERVATIONAL
Conditions
Summary
This study aims to evaluate the use of a prostate cancer specific predisposition genetic panel test in men with / at high risk of prostate cancer. The genetic test will analyse men's DNA samples for the presence of mutations in rare genes as well as common genetic variation to provide men with information about their risk of prostate cancer. This study will evaluate the clinical impact of the test on risk assessment and clinical management in terms of screening and treatment.
Eligibility
Inclusion Criteria9
- Affected cohort:
- Affected with PrCa \< 60 years or
- Affected with metastatic castration resistant PrCa (mCRPC) at any age or Aggressive PrCa Gleason 4+4 or higher \<70 years
- Affected with family history defined as three or more cases any age (FDR or SDR)
- Unaffected cohort: (This cohort is no longer recruiting, it has completed recruitment)
- Aged \>30 and with a family history defined as:
- FDR diagnosed \< 70
- or more cases in First or Second Degree Relatives (FDR/SDR) with one case diagnosed \< 70 years
- or more cases at any age (on same side of family)
Exclusion Criteria1
- • WHO performance status 4
Interventions
A list of genes created by study experts, thought to increase the risk of prostate cancer from from review previous research, this list is regularly reviewed for accuracy
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04763317